Skip to main content
A

Ab&B Bio-Tech CO., LTD. JS — Investor Relations & Filings

Ticker · 2627 HKEX Manufacturing
Open in API
Filings indexed 55 across all filing types
Latest filing 2025-08-08 Governance Information
Country HK Hong Kong
Listing HKEX 2627

About Ab&B Bio-Tech CO., LTD. JS

http://www.abbbio.com

Ab&B Bio-Tech CO., LTD. JS is a biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of human vaccines and biological preparations that confer active immunity. The company's mission centers on developing globally innovative vaccines and utilizing new technologies to improve traditional vaccines. Its comprehensive pipeline targets infectious diseases and includes candidates across viral, bacterial, conjugate, subunit, and mRNA platforms. The primary commercial product is the Quadrivalent Subunit Influenza Vaccine, approved for individuals aged six months and above. Advanced pipeline assets, such as the 23-valent Pneumococcal Polysaccharide Vaccine and the Freeze-dried Human Rabies Vaccine (Human Diploid Cell), have completed Phase I clinical trials. R&D operations are supported by facilities in Shanghai and Taizhou, with the company emphasizing scientific validation through publications in international journals.

Recent filings

Filing Released Lang Actions
ARTICLES OF ASSOCIATION
Governance Information Classification · 1% confidence The document is the Articles of Association of a listed company, detailing its internal rules, board structure, shareholder meetings, share issuance, governance procedures, and corporate constitution. This aligns with the definition of a Governance Information filing (CGR), which covers the company's internal rules and governance practices.
2025-08-08 English
POSTPONEMENT OF EXPECTED TIMETABLE OF THE GLOBAL OFFERING DUE TO BAD WEATHER
Share Issue/Capital Change Classification · 1% confidence The document is an HKEX announcement by Ab&B Bio-Tech regarding the postponement and updated timetable of its Global Offering (IPO) due to bad weather. It is not a full prospectus or annual/interim report, nor an AGM or earnings release. Instead, it provides details on the timing and procedures for the issuance and allotment of new H shares, fitting squarely into a share issuance announcement. Therefore, the correct classification is Share Issue/Capital Change (SHA).
2025-08-05 English
Documents on Display
Regulatory Filings Classification · 1% confidence The document is a placeholder message from the Hong Kong Exchanges and Clearing Limited stating that the requested document has been removed by the issuer. Since it does not contain any substantive financial or corporate information and serves as a system-generated notice regarding a missing filing, it falls under the general regulatory announcement category.
2025-07-31 English
GLOBAL OFFERING
Share Issue/Capital Change Classification · 1% confidence The document is a full prospectus detailing a global offering of new H Shares, including number of offer shares, offer price, application procedures, underwriting arrangements, and timetable. This is clearly an announcement and details of a new share issuance (initial public offering), fitting the Share Issue/Capital Change category.
2025-07-31 English
GLOBAL OFFERING
Capital/Financing Update Classification · 1% confidence The document is an announcement regarding the company’s Global Offering (IPO) of new H Shares, detailing the number of shares, offering structure, application procedures, pricing, allotment timetable, underwriting arrangements, etc. It is not the full prospectus itself but a public announcement of a major share issuance and fundraising. Such IPO/share issuance announcements fall under capital raising and financing activities, matching the “Capital/Financing Update” category.
2025-07-31 English
PHIP (1st submission)
Share Issue/Capital Change Classification · 1% confidence The document is a full IPO prospectus (“Post Hearing Information Pack”) for Ab&B Bio-Tech Co., Ltd., drafted to support a new H-share offering and listing on the Hong Kong Stock Exchange. It details share numbers, pricing, listing timetable, risk factors, business overview, financial information, sponsors, etc. This is not a simple announcement but the complete share issue prospectus, fitting the “Share Issue/Capital Change” category (new share issue).
2025-07-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.